Clinical trialsCompany release

Cerenome reports no dose-limiting toxicities in first 10 patients on repeat intraventricular REYOBIQ

🇺🇸 Cerenome, Inc. (CNSY) · Mon 16 Nov 2026

Interim Phase 1 ReSPECT-LM data suggest repeated intraventricular dosing of rhenium Re186 obisbemeda is feasible in leptomeningeal metastases from solid tumours; the drug remains investigational.

Cerenome announced on 16 November 2026 interim results from its Phase 1 ReSPECT-LM trial of repeated intraventricular REYOBIQ (rhenium Re186 obisbemeda) in patients with leptomeningeal metastases from solid tumours. The data were presented as a poster at the Society for Neuro-Oncology (SNO) annual meeting on 13 November.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Cerenome, Inc. ↗

Article written by VigiEye from the official source (Cerenome, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →